Drugs / Tetrabik
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03891758 Comparator | Apr → Sep 2019 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Tanabe Pharma Corporation | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetrabik | “concomitant vaccination with ActHIB® (Hib) and Tetrabik (DPT-IPV) as a comparator” PMID 38582691 ↗ Apr 2024 |
| Modality | Vaccine | “Hib (ActHIB®) and DPT-IPV quadrivalent vaccine (Tetrabik)” PMID 38582691 ↗ Apr 2024 |